stuartlpbi | Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Feeds:: Posts; Comments

About: Stuart Cantor

Website: http://stuartlpbi.wordpress.com
Details: I have a Ph.D. in pharmaceutical sciences and my expertise is in solid oral dosage formulation development and controlled-release technologies. I also have a deep background in intellectual property in the areas of chemistry, pharma, medical device, and biotech.

Posts by Stuart Cantor:

February 8, 2016 Bio-MEMS Technologies: Devices, Tissue Engineering & Drug Delivery, Presentation by Stuart Cantor, Ph.D. on 2/4/16

Follow Blog via Email

Enter your email address to follow this blog and receive notifications of new posts by email.

Email Address

Join 1,254 other subscribers
Recent Posts
- 2022 FDA Drug Approval List, 2022 Biological Approvals and Approved Cellular and Gene Therapy Products January 17, 2023
- Verily announced other organizational changes, 1/13/2023 January 16, 2023
- Mission 4: Use of Systems Biology for Design of inhibitor of Galectins as Cancer Therapeutic – Strategy and Software December 13, 2022
- Science Has A Systemic Problem, Not an Innovation Problem December 12, 2022
- Chemistry Nobelist Carolyn Bertozzi’s years at UC Berkeley October 24, 2022
- Technion #1 in Europe in Field of AI for 2nd Straight Year October 20, 2022
- Endoglin Protein Interactome Profiling Identifies TRIM21 and Galectin-3 as New Binding Partners October 11, 2022
- The drug efflux pump MDR1 promotes intrinsic and acquired resistance to PROTACs in cancer cells October 11, 2022
- Cancer Policy Related News from Washington DC and New NCI Appointments October 4, 2022
- Accelerating PROTAC drug discovery: Establishing a relationship between ubiquitination and target protein degradation October 4, 2022
Archives
Archives
Categories
Categories
Meta